Pegaptanib
- Generic Name
- Pegaptanib
- Drug Type
- Biotech
- CAS Number
- 222716-86-1
- Unique Ingredient Identifier
- 3HP012Q0FH
- Background
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.
Pegaptanib was granted FDA approval on 17 September 2004.
- Indication
For the treatment of neovascular (wet) age-related macular degeneration.
- Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
- Conditions
- Retinal Vein Occlusion
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2007-01-19
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT00088283
- Locations
- 🇺🇸
Jules Stein Institute, Los Angeles, California, United States
🇺🇸Orange County Retina Associates, Santa Ana, California, United States
🇺🇸Cumberland Valley Retina Center, Hagerstown, Maryland, United States
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
- Conditions
- Macular Degeneration
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2005-08-30
- Lead Sponsor
- Eyetech Pharmaceuticals
- Registration Number
- NCT00088192
- Locations
- 🇺🇸
Eye Foundation of Kansas City, Kansas City, Missouri, United States
🇺🇸The Eye Center of Concord, Concord, New Hampshire, United States
🇺🇸Retina Associates of Cleveland Inc., Lakewood, Ohio, United States
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
- Conditions
- Hippel-Lindau Disease
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 5
- Registration Number
- NCT00056199
- Locations
- 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
- Conditions
- Diabetic Macular Edema
- First Posted Date
- 2002-06-25
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- Eyetech Pharmaceuticals
- Registration Number
- NCT00040313
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.